Boehringer Ingelheim to collaborate with Phenomic AI on stroma-rich cancers

Boehringer Ingelheim to collaborate with Phenomic AI on stroma-rich cancers

Source: 
Medical Marketing and Media
snippet: 


Boehringer Ingelheim has inked a deal worth up to $509 million with biotech Phenomic AI to develop new targets in stroma-rich cancers, the companies announced Wednesday. Boehringer Ingelheim will pay $9 million immediately and up to $500 million in potential milestones.